Staphylococcus aureus pore-forming toxins (S. aureus PFTs)

Staphylococcus aureus pore-forming toxins (PFTs) are a critical class of secreted virulence factors that facilitate bacterial survival, tissue invasion, and immune evasion [1.1.1, 1.3.1]. This group includes the single-component alpha-hemolysin (Hla or alpha-toxin) and several bicomponent leukocidins, such as Panton-Valentine Leukocidin (PVL), Leukocidin ED (LukED), and Leukocidin AB (LukAB) [1.2.1, 1.3.2]. These toxins function by binding to specific host cell receptors—such as the metalloprotease ADAM10 for Hla or various chemokine and complement receptors for leukocidins—and subsequently oligomerizing to form stable, unregulated beta-barrel pores in the plasma membrane [1.1.2, 1.2.4]. The resulting pores cause rapid osmotic lysis of immune cells (neutrophils, macrophages) and structural cells (epithelial, endothelial), leading to severe clinical manifestations including necrotizing pneumonia, sepsis, and deep-seated skin infections [1.2.1, 1.6.1]. As therapeutic targets, S. aureus PFTs are the focus of anti-virulence strategies designed to disarm the pathogen without exerting the direct selective pressure associated with traditional antibiotics [1.3.3, 1.6.1]. Current drug development efforts primarily involve monoclonal antibodies, such as suvratoxumab and tosatoxumab, which neutralize the toxins to prevent host cell damage and preserve the innate immune response [1.1.1, 1.5.4]. These therapies are intended as adjunctive treatments to standard-of-care antibiotics, particularly for managing infections caused by multi-drug resistant strains like MRSA, where toxin-mediated tissue destruction significantly contributes to patient morbidity and mortality [1.3.1, 1.5.2].

Other names

Staphylococcal pore-forming toxinsS. aureus cytotoxinsStaphylococcal hemolysins and leukocidinsS. aureus beta-barrel pore-forming toxinsStaphylococcal cytolytic toxins

Neutralization of toxin monomers to prevent binding to host receptors (e.g., ADAM10, CCR5, CXCR1/2), inhibition of toxin self-oligomerization on the host cell membrane, and blocking of the resulting transmembrane pore to prevent ion flux and subsequent cytolysis [1.1.1, 1.2.1, 1.3.3].